Immunotherapy Plus Chemotherapy Raises Pathologic Complete Response in Early HR-Positive Breast Cancer
Immunotherapy combined with standard neoadjuvant chemotherapy has shown encouraging benefits in hormone receptor positive, HER2 negative early breast cancer, according to new evidence.